Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Triple inhaler shows promise for COPD sufferers

NCT ID NCT01917331

Disease control Sponsor: Chiesi Farmaceutici S.p.A. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This phase 3 trial tested a new triple-combination inhaler (beclometasone, formoterol, and glycopyrrolate) against a standard two-drug inhaler in 1,368 adults with severe COPD. The study measured changes in lung function and breathlessness over 52 weeks. The goal was to see if the triple therapy provides better symptom control and fewer flare-ups.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Beclometasone, formoterol, and glycopyrrolate (triple-combination inhaler)
What this could lead to
If successful, this triple inhaler could offer better lung function and symptom control for people with severe COPD compared to current two-drug inhalers.
What could go wrong
This is a completed phase 3 trial, but results may not apply to all COPD patients. The triple inhaler may cause more side effects (e.g., throat irritation, pneumonia) and may not improve quality of life for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

1,368 people

The number who actually took part.

Started

Mar 2014

Finished

Jan 2016

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female adults aged ≥ 40 years with a diagnosis of COPD * Current smokers or ex-smokers * A post-bronchodilator Forced Expiratory Volume in the 1st Second (FEV1) \< 50% of the predicted normal value and a post- bronchodilator FEV1/ Forced Vital Capacity (FVC) \< 0.7 * At least one exacerbation in the 12 months preceding the screening visit Exclusion Criteria: * Pregnant or lactating women * Diagnosis of asthma or history of allergic rhinitis or atopy * Patients treated with non-cardioselective β-blockers in the month preceding the screening visit * Patients treated for exacerbations in the 4 weeks prior to screening visit * Patients treated with long-acting antihistamines unless taken at stable regimen at least 2 months prior to screening and to be maintained constant during the study or if taken as PRN * Patients requiring long term (at least 12 hours daily) oxygen therapy for chronic hypoxemia * Known respiratory disorders other than COPD * Patients who have clinically significant cardiovascular condition

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease lung disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic obstructive pulmonary disease (COPD)

Contacts and locations

Locations

  • Dr Beatrix BALINT

    Szeged, 6722, Hungary

More trials for these conditions

Other studies related to the condition(s) this trial covers.